LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
Recruiting now · Phase 4
Conditions studied: Angina, Stable Ischemic Heart Disease
In brief
To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).
Key facts
- Study ID
- NCT05786417
- Run by
- Yale University
- People needed
- 741
- Starts
- 2023-05-10
- Expected to finish
- 2027-05-30
- Last updated by the study team
- 2026-04-07
Who can join
Age: 65 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- OLDER ADULTS WITH SIHD AND MCC
- Age ≥65 years
- ≥ 2 Multiple Chronic Conditions as defined by Centers for Medicare and Medicaid Services (CMS)
- Diagnosis of Symptomatic Stable Ischemic Heart Disease with plans to initiate medical therapy identified by at least one of the following:
- positive non-invasive functional or anatomic testing suggestive of obstructive coronary artery disease
- coronary angiography with stenosis ≥70% in a coronary artery ≥2 mm in diameter or
- ≥50% stenosis of left main
- Invasive coronary angiography with positive physiologic testing in at least one vessel (FFR ≤ 0.80 or iFR ≤0.89)
- CAREGIVERS
- Age ≥ 18 years
- Identified as caregiver of LIVEBETTER participant
You may not qualify if…
- OLDER ADULTS WITH SIHD AND MCC
- Current taking (both) a beta-blocker AND a calcium channel blocker*
- Contraindication to beta-blockers or calcium channel blockers including:
- significant hypotension
- high grade AV block
- severe symptomatic bradycardia
- severe obstructive lung disease
- Documented intolerance to beta-blockers or calcium channel blockers
- Probable or definite high-risk coronary artery disease including unrevascularized left main disease and/or unrevascularized multi-vessel disease including the proximal left anterior descending (LAD) artery with plans for immediate complete revascularization
- Plans for complete revascularization within 2 weeks
- Clear clinical indication for beta-blockers or calcium channel blockers that precludes dose adjustment or crossover:
- Diagnosis of acute coronary syndrome (ACS) with reduced ejection fraction within past year
- Heart failure with reduced ejection fraction (HFrEF) within past year
- Actively participating in another clinical trial involving an investigational medication or device
- Primary language other than English or Spanish
- Inability to complete follow-up (e.g. life expectancy <12 months, impaired decision-making determined by validated instrument)
- Previously enrolled in LIVEBETTER
- Refused informed consent
- CAREGIVERS
- Professional caregiver (i.e. not a relative or close friend of the participant)
- Primary language other than English or Spanish
- Inability to complete follow-up
- Previously enrolled in LIVEBETTER
- Refused informed consent
Where it is running
- Yale School of Medicine — New Haven, Connecticut, United States (enrolling)
- Wellstar Research Institute — Marietta, Georgia, United States (enrolling)
- Cook County Health — Chicago, Illinois, United States (enrolling)
- Brigham and Women's Hospital — Boston, Massachusetts, United States (enrolling)
- Mt. Sinai Health System — New York, New York, United States (enrolling)
- Duke University, School of Medicine — Durham, North Carolina, United States (enrolling)
- Inova Health Care Services — Fairfax, Virginia, United States (enrolling)
- Nirvana Integrative Medicine — New York, New York, United States (enrolling)
- NYC Health and Hospitals, Harlem Hospital — New York, New York, United States
- Cleveland Clinic — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.